Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Dicot Pharma AB is a pioneering biotechnology company engaged in the development of novel pharmaceuticals primarily within the field of sexual dysfunction and related areas. Founded with the aim of enhancing quality of life, the company's flagship product is focused on creating a long-lasting treatment for erectile dysfunction, offering a promising alternative to currently available solutions. Dicot Pharma’s primary approach involves the utilization of pharmacological research and advanced clinical trials, positioning itself as a key player in the sexual wellness sector of the pharmaceutical industry. The firm's innovative methodology in drug development emphasizes safety, efficacy, and extended therapeutic benefits, catering to a globally expanding market need. Based in Sweden, Dicot Pharma benefits from the country's strong biotech infrastructure, facilitating robust research and development activities. The company's commitment to developing cutting-edge therapies underscores its role in the competitive landscape of pharmaceuticals, contributing to advancements in medical science and patient care worldwide.
kr 0.01
kr 0.00 (-7.24%)
EOD Jun 23, 2026 · Twelve Data
ROIC dropped from -60.02% to -70.56%, capital efficiency is deteriorating. Negative free cash flow of -kr 86M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
kr 0.00
Net Income (FY)
-kr 80M
▼ -39.1% YoY
Op. Margin
—
ROIC
-70.56%
▼ -10.5pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-kr 86M
▼ -45.8% YoY
Op. Cash Flow (FY)
-kr 86M
▼ -45.8% YoY
Net Debt
-kr 69M
Net Cash Position
Cash & Equiv.
kr 69M
Continue Research
Dicot Pharma AB (DICOT.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Dicot Pharma AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Dicot Pharma AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -70.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh DICOT.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.